Live Feeds
● LIVE Updated 57m ago · 5 sources tracked

Novo Nordisk to Pay Up to $1.3 Billion for Nanexa’s Drug Delivery Technology

Wegovy maker Novo Nordisk has agreed to pay up to $1.3 billion for Nanexa drug delivery technology, prompting a major surge in Nanexa shares. The agreement involves injection technology worth €1.17 billion, allowing Novo Nordisk to pursue long-acting obesity drugs. The multi-million-dollar deal unlocks long-acting obesity injectables for the pharmaceutical company, driving a significant 150 percent surge in the pharmaceutical stock on the market following the announcement of the injectables partnership.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (5)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Novo Nordisk is paying up to $1.3 billion for Nanexa’s drug delivery technology.
  • ✓ The transaction value is noted at €1.17 billion in connection with the injection technology deal.
  • ✓ Nanexa shares soared following the announcement of the injectables deal with the Wegovy maker.
  • ✓ The agreement is aimed at unlocking long-acting obesity injectables.
🛡️ Source Corroboration: 5 independent reporting domains (100% confidence) ⏱ Read time: ~2 min

What changed

Novo Nordisk reached a deal worth up to $1.3 billion to secure Nanexa's drug delivery technology for long-acting obesity treatments.

Live updates

  1. Novo Nordisk to Pay Up to $1.3B for Nanexa Technology

    Wegovy maker Novo Nordisk has agreed to pay up to $1.3 billion for Nanexa drug delivery technology, prompting a major surge in Nanexa shares. The agreement involves injection technology worth €1.17 billion, allowing Novo Nordisk to pursue long-acting obesity drugs. The multi-million-dollar deal unlocks long-acting obesity injectables for the pharmaceutical company, driving a significant 150 percent surge in the pharmaceutical stock on the market following the announcement of the injectables partnership.

    Why it matters

    The acquisition targets advanced drug delivery technology to support long-acting treatments for obesity. Novo Nordisk continues to expand its pipeline for weight management products through external partnerships. Financial terms place the ceiling of the agreement near $1.3 billion or €1.17 billion.

    What is confirmed

    • Novo Nordisk is paying up to $1.3 billion for Nanexa’s drug delivery technology.
    • The transaction value is noted at €1.17 billion in connection with the injection technology deal.
    • Nanexa shares soared following the announcement of the injectables deal with the Wegovy maker.
    • The agreement is aimed at unlocking long-acting obesity injectables.

    What to watch next

    • Further announcements regarding the clinical development timelines for long-acting obesity injectables using Nanexa's technology.
    • Regulatory filings or financial disclosures detailing the milestone payment schedule of the $1.3 billion deal.
    Sources used for this update (5)
    1. WSJ — Novo Nordisk to Pay Up to $1.3 Billion for Nanexa’s Drug Delivery Technology
    2. CNBC — Pharma stock soars 150% on injectables deal with Wegovy maker Novo
    3. reuters.com — Nanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
    4. finance.yahoo.com — Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
    5. Fierce Biotech — Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables
    confidence 100%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community